Lipton, Richard B.
Contreras-De Lama, Janette
Serrano, Daniel
Engstrom, Ella
Ayasse, Nicolai D.
Poh, Weijie
Cadiou, François
Manack Adams, Aubrey
Funding for this research was provided by:
Allergan Foundation
Article History
Received: 11 July 2023
Accepted: 2 October 2023
First Online: 1 November 2023
Declarations
:
: Richard B. Lipton, MD, has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Dr. Reddy’s Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff’s Headache</i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock in Biohaven and Manistee. Janette Contreras-De Lama, PhD, and Aubrey Manack Adams, PhD, are employees of AbbVie and may hold AbbVie stock. Daniel Serrano, PhD, and Ella Engstrom, BS, were employees of OPEN Health Group at the time of the study. Nicolai D. Ayasse, PhD, was an employee of OPEN Health Group at the time of the study and is currently an employee of Critical Path Institute. Weijie Poh, PhD, was an employee of Healint Pte Ltd at the time of the study and is currently an employee of Digital Life Line. François Cadiou, MBA, is an employee of Healint Pte Ltd.
: Potentially eligible participants were screened to determine eligibility, consented electronically to participate in the study, and then enrolled in the study. Participants were informed their personal study-related data would be used in accordance with local privacy and data protection laws. The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by Advarra Institutional Review Board in the USA (Pro00045512).